Other TKIs

PreclinicalSmall molecule

Bayer

Other TKIs is one of 69 small molecule programs targeting Thyroid Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid CancerActive, not recruiting

COVID-19Active, not recruiting

Thyroid CancerPreclinical

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Competition

Competitive Landscape

309 competitors in COVID-19

#DrugCompanyPhaseTrials

Statins

Sanofi

Preclinical

1 2

Rayaldee

OOrganon and Co

Preclinical

1 3

SARS-COV-2 VACCINE

Moderna

Preclinical

2 4

Blood Taken

HHospices Civils de Lyon

Preclinical

1 5

Disease-Modifying Anti-Rheumatic Drugs

Roche

Preclinical

1 6

Covid Infection

KKing's College London

Preclinical

1 7

Standard Preparation

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

1 8

Immunosuppressive

Chiesi Farmaceutici S.p.A.

Preclinical

1 9

Other TKIs

Bayer

Preclinical

1 10

Serology Test

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rivaroxaban2 trials

A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

Completed· Bayer logo

Bayer··NCT05112666·2,601 enrolled

A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)

Completed· Bayer logo

Bayer··NCT05150938·5,737 enrolled

Oral1 trial

Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being

Completed· Bayer logo

Bayer··NCT00988910·632 enrolled

Thyroid Cancer1 trial

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

Completed· Bayer logo

Bayer··NCT02303444·667 enrolled

COVID-191 trial

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib

Completed· Bayer logo

Bayer··NCT05594147·4,103 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Other TKIs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Other TKIs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Other TKIs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

Other TKIs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rivaroxaban2 trials

Oral1 trial

Thyroid Cancer1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News